These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 29536125)

  • 1. [Treatment of acute and recurrent Clostridium difficile infections : What is new?].
    von Braun A; Lübbert C
    Internist (Berl); 2018 May; 59(5):505-513. PubMed ID: 29536125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New Guidelines and Data to Clostridium difficile - What's New?].
    Lübbert C; Lippmann N; von Braun A
    Dtsch Med Wochenschr; 2018 Jun; 143(11):787-792. PubMed ID: 29807377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging drugs for the treatment of clostridium difficile.
    Cammarota G; Gallo A; Ianiro G; Montalto M
    Expert Opin Emerg Drugs; 2019 Mar; 24(1):17-28. PubMed ID: 30841760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Individualized treatment strategies for Clostridium difficile infections].
    Solbach P; Dersch P; Bachmann O
    Internist (Berl); 2017 Jul; 58(7):675-681. PubMed ID: 28589214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update of treatment algorithms for Clostridium difficile infection.
    Ooijevaar RE; van Beurden YH; Terveer EM; Goorhuis A; Bauer MP; Keller JJ; Mulder CJJ; Kuijper EJ
    Clin Microbiol Infect; 2018 May; 24(5):452-462. PubMed ID: 29309934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin?
    Manthey CF; Eckmann L; Fuhrmann V
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1239-1250. PubMed ID: 28766951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clostridioides difficile - New Insights and Therapy Recommendations].
    Schönherr S; Jung L; Lübbert C
    Dtsch Med Wochenschr; 2023 Jun; 148(12):752-758. PubMed ID: 37257477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clostridium difficile infection in older adults: a review and update on its management.
    Kee VR
    Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Crawford T; Huesgen E; Danziger L
    Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.
    Ajami NJ; Cope JL; Wong MC; Petrosino JF; Chesnel L
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463537
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.
    Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA
    J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of adult Clostridium difficile digestive contaminations: a literature review.
    Mathias F; Curti C; Montana M; Bornet C; Vanelle P
    Eur J Clin Microbiol Infect Dis; 2019 Feb; 38(2):209-231. PubMed ID: 30498879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical review of Clostridium difficile infection: an update on treatment and prevention.
    Daniels LM; Kufel WD
    Expert Opin Pharmacother; 2018 Nov; 19(16):1759-1769. PubMed ID: 30220230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with
    Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X
    Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring ways to improve CDI outcomes.
    Galpérine T; Guery B;
    Med Mal Infect; 2018 Feb; 48(1):10-17. PubMed ID: 29336930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and management of Clostridium difficile infection.
    Dupont HL
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1216-23; quiz e73. PubMed ID: 23542332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
    Miller M
    Expert Opin Pharmacother; 2010 Jun; 11(9):1569-78. PubMed ID: 20446864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European Practice for CDI Treatment.
    Fitzpatrick F; Brennan R; van Prehn J; Skally M; Brady M; Burns K; Rooney C; Wilcox MH
    Adv Exp Med Biol; 2024; 1435():57-84. PubMed ID: 38175471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    Cornely OA
    Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Best strategies in recurrent or persistent Clostridium difficile infection.
    Cocanour CS
    Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.